	US 11,786,550 B2
	gRNA targeting HPK1 and a method for editing HPK1 gene
Xuebin Liao, Beijing (CN); and Jingwen Si, Beijing (CN)
Assigned to Beijing Synthetic Vaccine Biosciences Co., Ltd, Beijing (CN)
Appl. No. 16/648,907
Filed by Beijing Synthetic Vaccine Biosciences Co., Ltd, Beijing (CN)
PCT Filed Sep. 20, 2018, PCT No. PCT/CN2018/106636 § 371(c)(1), (2) Date Mar. 19, 2020, PCT Pub. No. WO2019/057102, PCT Pub. Date Mar. 28, 2019.
Claims priority of application No. 201710853090.2 (CN), filed on Sep. 20, 2017.
Prior Publication US 2022/0023340 A1, Jan. 27, 2022
Int. Cl. A61K 35/17 (2015.01); A61P 35/00 (2006.01); C12N 9/22 (2006.01); C12N 15/113 (2010.01)

CPC A61K 35/17 (2013.01) [A61P 35/00 (2018.01); C12N 9/22 (2013.01); C12N 15/1137 (2013.01); C12Y 207/11001 (2013.01)]

6 Claims

1. A human immune cell comprising a genetic disruption of a HPK-1 gene, wherein the immune cell further comprises a recombinant receptor expressed on the surface of the immune cell or a polynucleotide encoding the recombinant receptor, wherein the recombinant receptor specifically binds to an antigen, and wherein the immune cell is capable of inducing enhanced cytotoxicity upon binding of the recombinant receptor to the antigen on a target cell compared to a control immune cell not comprising a genetic disruption of the HPK-1 gene.